Dissecting the mechanisms of pazopanib in soft tissue sarcoma

Principal Investigators: 
Institution: 
Award Amount: 
£31,301
Duration: 
1 year

Pazopanib, a drug that targets a class of genes known as ‘kinases’, was recently approved for the treatment of advanced sarcoma.  While some patients respond well to pazopanib, the drug does not work in all cases, meaning that some patients are exposed to the potential side effects of the treatment for little or no benefit.  At present, it is challenging to predict who will respond to pazopanib, and it would be helpful to find tumour markers that enable doctors to identify the right patients to administer the drug.  Furthermore, because it is unknown as to why some patients do not respond t

Identifying which genes make a person more likely to develop sarcoma

Principal Investigators: 
Institution: 
Award Amount: 
£92,365

This project is using the latest technology to sequence the DNA samples from hundreds of people with sarcoma. By doing this the group hope to identify the genes which make a person susceptible to developing sarcoma. Any genes found can then be used as the basis of future genetic testing to identify patients who are at high risk.

Pages